2025年11月6日,诺和诺德、礼来与美国政府达成历史性降价协议,GLP-1类药物的价格天花板被打破。联邦医保受益人每月在GLP-1类药物上自付仅50美元,在医保计划之外,则以每月350美元的均价向消费者直售,两年内价格可能还会下调至250美元左右,这一政策的出台,也能看到美国应对减重问题的步伐更加坚定。而在中国,司美格鲁肽这一新晋“药王”正迎来一场药企竞逐的激烈局面。当美国用“降价+ 医保覆盖”...
Source Link2025年11月6日,诺和诺德、礼来与美国政府达成历史性降价协议,GLP-1类药物的价格天花板被打破。联邦医保受益人每月在GLP-1类药物上自付仅50美元,在医保计划之外,则以每月350美元的均价向消费者直售,两年内价格可能还会下调至250美元左右,这一政策的出台,也能看到美国应对减重问题的步伐更加坚定。而在中国,司美格鲁肽这一新晋“药王”正迎来一场药企竞逐的激烈局面。当美国用“降价+ 医保覆盖”...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.